TABLE 1.

BMS-488043 sensitivities of uncloned HIV-1 envelopes from subjects before and during BMS-488043 administration

Subject	BMS-488043 dose (mg)	EC50 (nM)		Max decrease in HIV-1 RNA [log10 copies/ml (day)]
		Baselined	Day 8e
1	800	7	244a	0.49 (6)
2	800	3	20	1.17 (6)
3	Placebo	1	2	0.38 (6)
4	800	10	1,792a	0.64 (7)
5	800	66	358	0.33 (5)
6	Placebo	7	12	0.22 (2)
7	800	4	6b	0.87 (12)b
8	800	29	29	0.98 (7)
9	800	5	3	1.13 (9)
10	800	>10,000	>10,000	0.36 (5)
11	800	70	358	0.50 (5)
12	800	6	9	1.53 (10)
13	800	10	10	1.37 (8)
14	800	3	5	1.51 (10)
15	Placebo	10	13	0.30 (9)
16	Placebo	4	14	0.17 (6)
17	1,800	78	80	2.05 (9)
18	1,800	2	6	1.88 (9)
19	1,800	373	251	0.31 (5)
20	1,800	1	1	1.70 (10)
21	1,800	3	895a	0.81 (8)
22	1,800	7	5	1.14 (5)
23	1,800	6	2	1.69 (9)
24	Placebo	5	28	0.11 (8)
25	1,800	5	416a	0.38 (5)
26	1,800	5	4	1.32 (9)
27	1,800	813	864	0.24 (7)
28	1,800	60	19	1.06 (8)
29	1,800	6	4	1.33 (9)
30	Placebo	>10,000	>10,000	NDc

^aSubject whose virus, by definition (>10-fold increase in EC₅₀), developed resistance.

^bSamples for days 7 to 10 not available for this subject; day 12 sample used.

^cND, no decrease in HIV-1 RNA was noted for this subject during the study.

^dMedian, 6.

^eMedian, 19.